Skip to main content
Premium Trial:

Request an Annual Quote

Provista Receives CAP Accreditation for CLIA Lab

NEW YORK (GenomeWeb) – Provista Diagnostics said today that its Scottsdale Ariz.-based CLIA-certified laboratory has received accreditation from the College of American Pathologists.

Provista is a molecular diagnostics firm focused on blood-based proteomic tests for disease including breast and ovarian cancer. Additionally, the company offers diagnostic development services to outside firms through its CLIA facility.

"For development of our own proprietary diagnostics, as well as our work developing companion diagnostics for other companies, CAP accreditation signifies additional assurance that our lab operates under the highest quality standards to generate highly accurate and reliable results." Provista President and CEO David Reese said in a statement.

The CAP Laboratory Accreditation Program involves inspections of clinical lab records and quality control procedures and assessments of a lab's staff qualifications, equipment, facilities, safety program, and overall management.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.